GLPwatch
Papers (10389)
Page 169 of 174, ranked by citation count.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
- Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
- Economic Evaluation of Medications in Prevention and Treatment of Obesity: A Systematic Review.
- Economic evaluation of liraglutide vs dulaglutide or oral semaglutide in patients with type 2 diabetes mellitus: a systematic review.
- Probable tirzepatide-associated limbic encephalitis with status epilepticus in a patient with extreme obesity: a case report.
- Efficacy of Anti-Obesity Medications in Adult and Older Adult Veteran Populations.
- A Short-Term Cost-Effectiveness Analysis of Tirzepatide Versus Semaglutide for the Treatment of Obesity in Greece.
- Comparing Real-World Effectiveness of Dulaglutide and Insulin as the First Injectable for Patients with Type 2 Diabetes: An Australian Single-Site Retrospective Chart Review.
- Tirzepatide.
- Assessing the impact of the Inflation Reduction Act on Medicare prescription drug coverage.
- Benchmarking size-exclusion chromatography columns for the analysis of therapeutic peptides and model oligonucleotides.
- Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Thyroid Function Tests: A Systematic Review Identifying a Critical Evidence Gap.
- Comparison of cardiovascular outcomes between once-weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States.
- Exendin-4 enhances GLP-1 signaling and reduces anxiety-like behaviors in male heroin withdrawal mice.
- Cellular loci for cagrilintide action identified.
- [Victoza changes diabetes and lives of patients 5 years already].
- Targeting Multiple Gut-Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy.
- Liraglutide as First-Line Therapy for Type 2 Diabetics With Post-COVID-19 Fatigue Syndrome and Executive Function Deficits.
- Decoding the hallmarks of GLP-1RA weight-loss super-responders.
- GLP-1RA- and Incretin-Based Therapies Within Lifestyle Interventions for Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis.
- Prescribing of GLP-1 and GIP/GLP-1 Receptor Agonists and Other Glucose-Lowering Drugs Requiring Special Caution in Elderly Japanese People With Type 2 Diabetes: A Preliminary Report.
- Oral Delivery of Liraglutide Formulated with PLGA for Sustained Obesity Management.
- Efficacy of tirzepatide in glycemic control and weight management in adults with type 2 diabetes: a systematic review and meta-analysis of real-world studies.
- Microbiota-driven gut-brain signaling underlies antidepressant effects of a GLP-1 analog.
- [Liraglutide in the treatment of obesity : a multidisciplinary approach].
- Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes.
- ATR-FTIR spectroscopy coupled with multivariate analysis for monitoring degradation and secondary structure transitions in therapeutic peptide formulations.
- Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes.
- Effect of GLP-1 receptor agonists on idiopathic intracranial hypertension: A systematic review.
- [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
- From In Vitro Efficacy to Long-Term HbA1c Response for GLP-1R/GlucagonR Agonism Using the 4GI-HbA1c Systems Model.
- Beyond weight loss: multisystem benefits of obesity medications.
- A Validated, Stability-Indicating HPLC Method for the Simultaneous Determination of Five Related Substances in Liraglutide Drug Substance.
- Patient-Reported Adverse Events with Adjunctive Tirzepatide or Semaglutide Treatment in Adults with Type 1 Diabetes.
- Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH.
- Treatment of the disease of obesity in patients with type 1 diabetes with tirzepatide: a protocol for a randomised controlled trial in a single-centre setting.
- Is it time to reassess the role of myocardial metabolic modulation for the treatment of heart failure?
- Emulating the LEADER trial in China: a regulatory science case study on non-interventional research.
- Hypercalcemia Induced by Tirzepatide and Calcium Supplementation: A Case Report.
- Association Between Semaglutide or Tirzepatide Therapy and Residual Gastric Content: A Potential Danger During Upper Endoscopy.
- Differential impact of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss in the type 2 diabetic and non-diabetic populations.
- Clinical factors influencing the systolic blood pressure benefits of once-weekly semaglutide in patients with type 2 diabetes.
- How does survodutide work? Plain language review of a potential new medication for obesity and liver disease.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
- Comparative efficacy and safety of three fixed-ratio combination products in type 2 diabetes: A network meta-analysis.
- National Poison Center Trends in GLP-1 Receptor Agonist Exposures Following FDA Approval for Weight Loss.
- In brief: Wegovy HD - high-dose injectable semaglutide for weight loss.
- Preventive effect of liraglutide on postoperative delirium in elderly patients undergoing cardiac surgery: protocol for a single-centre, randomised, double-blind, placebo-controlled trial.
- A multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice (PIONEER REAL Japan): Subgroup analyses.
- Tirzepatide Versus Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes With Established Cardiovascular Disease: An Indirect Treatment Comparison Meta-Analysis.
- The Use of Glucagon-Like Peptide 1 Agonists Among Non-Diabetics: Evidence From Medicare Part D.
- [Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
- Web Exclusive. Annals On Call - Dulaglutide, Semaglutide, and Tirzepatide: How Do Gastrointestinal Adverse Effects Compare?
- New drugs: Liraglutide, dalfampridine, and abobotulinumtoxinA.
- Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus.
- Real world study of GLP-1 receptor agonists in overweight or obese type 2 diabetes by using repeated measurement analysis of variance.
- Efficacy and safety of GLP-1 receptor agonists in the treatment of type 2 diabetes and/or obesity in patients with Cushing’s syndrome: a multicenter retrospective study.
- Possible protective effects of tirzepatide on polycystic ovary syndrome in female rat model induced by testosterone propionate in comparison to metformin.